A Phase 1, Open-label, Dose-escalation Study of SNX 5422 Plus Carboplatin and Paclitaxel in Subjects With Selected Solid Tumors.

Trial Profile

A Phase 1, Open-label, Dose-escalation Study of SNX 5422 Plus Carboplatin and Paclitaxel in Subjects With Selected Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs SNX 5422 (Primary) ; Carboplatin; Paclitaxel
  • Indications Non-small cell lung cancer; Small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Esanex
  • Most Recent Events

    • 25 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 02 Jun 2017 Results assessing the safety and efficacy of SNX-2112 in combination with carboplatin + paclitaxel in patients with advanced non-small-cell lung cancer, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 25 Apr 2017 Planned End Date changed from 1 Apr 2017 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top